These are relative terms. If I license a product from you, I am in-licensing it and you are out-licensing it. […]
What is in licensing and out licensing in pharmaceutical sector? Read Post »
This is a guest post from Avneet Heer, a student in the MS Biotechnology BioBusiness Track at Georgetown University. Do
How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds?
Biotech venture capital investments in public equities and performance Read Post »
How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What
Leaving money on the table in venture-backed biotechnology IPOs Read Post »
After months of development and feedback from customers, DrugPatentWatch is proud to announce the availability of two new datasets: Bulk
New features from DrugPatentWatch – Bulk API sources and clinical trials Read Post »
This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?
Biotech in Countries Starting with “I” – Part 11: Italy (secondo) Read Post »
The latest on what the Trump presidency means for health care, hospitals, drug companies, and medical research. Tuesday, Nov. 15
Trump in 30 seconds: Science and medicine in flux Read Post »
The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries
Which drug makers do a good job getting poor patients access to their medicines? Read Post »
To date, the Patent Trial and Appeal Board has reached a final decision in eight instituted inter partes review (IPR)